Core Viewpoint - The announcement details the completion of the China Securities Regulatory Commission (CSRC) filing for the conversion of certain unlisted shares of Fosun Pharma's subsidiary, Fuhong Hanlin, into H-shares for listing on the Hong Kong Stock Exchange [2][3]. Group 1: Filing Situation - Fuhong Hanlin has received a filing notice from the CSRC regarding the conversion of a total of 182,645,856 shares held by several shareholders into H-shares, including 120,000,000 shares held by Fosun Pharma's subsidiary, Fosun New Drug [3]. Group 2: Impact on the Listed Company - As of the announcement date, the company holds a total of 344,730,800 shares in Fuhong Hanlin, representing approximately 63.43% of its total share capital. The conversion of the 120,000,000 unlisted shares into H-shares will not change the total number of shares held by the company, which will remain at 152,331,100 H-shares and 192,399,700 unlisted shares [4]. - The company has no plans to reduce its holdings in Fuhong Hanlin, reflecting confidence in the development and value of Fuhong Hanlin and its subsidiaries [2][4].

证券代码：600196 股票简称：复星医药 编号：临 2026-006 上海复星医药（集团）股份有限公司 关于控股子公司部分境内未上市股份 申请全流通完成中国证监会备案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 ●控股子公司复宏汉霖若干名股东合计持有的182,645,856股复宏汉霖境内 未上市股份转为境外上市股份（即H股）并于香港联交所上市流通的申请事项， 已完成中国证监会备案；其中，本公司控股子公司复星新药持有的120,000,000 股复宏汉霖非上市股可转换为H股。如该等股份全数获转换后，本公司通过若干 控股子公司合计所持有复宏汉霖股份总数保持不变，其中H股152,331,100股、非 上市股192,399,700股。 ●基于对复宏汉霖及其控股子公司发展的信心及价值的认可，截至本公告日 期，本集团尚无减持复宏汉霖股份的计划。 一、备案情况 近日，本公司控股子公司复宏汉霖（于香港联交所主板上市，股份代码：02696） 收到中国证监会出具的《备案通知书》，其若干名股东将所持合计182,645,856 ...

上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 中國，上海 2026 年1 月1 6 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生、王可心先生及劉毅先生；本公 司之非執行董事為陳啟宇先生及潘東輝先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、Chen Penghui先生及楊玉成先生；以及本公司職工董事為嚴佳女士。 * 僅供識別 证券代码：600196 股票简称：复星医药 编号：临 2026-006 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」） ...

Group 1: Regulatory Developments - The National Healthcare Security Administration (NHSA) is soliciting public opinions on the "Guidelines for Real-World Comprehensive Value Assessment of Drugs" to establish a unified national evaluation system [1] - Huadong Medicine's subsidiary received FDA approval for clinical trials of DR10624, a novel drug targeting metabolic-associated fatty liver disease [1] - Fosun Pharma's subsidiary has had its drug registration application for erythromycin lactobionate injection accepted by the National Medical Products Administration [2] - Stone Pharmaceutical's new drug for hypertension has received FDA approval for clinical trials in the U.S. [3] - Zhi Mei Ru Kang's siRNA therapy for ALS has entered Phase 2 clinical trials [4] Group 2: Market and Corporate Developments - Cap Bio's major shareholders have increased their stake from 31.52% to 33.05% following capital changes and share buybacks [5] - Bluestar Medical's product is expected to be selected for national centralized procurement of drug-coated balloons, which could enhance its market presence [7] - NVIDIA and Eli Lilly have announced a $1 billion collaboration to establish an AI innovation lab focused on drug discovery and development [8] - Dr. Wang Qiang has transitioned from Xiansheng Pharmaceutical to Ganli Pharmaceutical as Senior Vice President and Chief Strategy Officer [9] Group 3: Quality Control and Safety - China Resources Double Crane has addressed recent quality issues with sodium bicarbonate injection products, clarifying that non-compliance was due to packaging issues during transport [10]

Core Viewpoint - Fosun Pharma (600196) is focusing on innovation and internationalization strategies while continuously monitoring cutting-edge technology trends and evaluating potential business opportunities based on market conditions, technological advancements, and the company's development plans [1] Group 1 - The company is actively engaging with investors through interactive platforms to address inquiries [1] - Fosun Pharma emphasizes the importance of aligning its strategies with market dynamics and technological progress [1] - The company is committed to exploring new business opportunities in relevant fields [1]

Core Viewpoint - Fosun Pharma's subsidiary, Suzhou Er Ye Pharmaceutical, has recently had its drug registration application for injectable erythromycin lactobionate accepted by the National Medical Products Administration of China [1] Group 1: Drug Information - The drug is a chemical medication intended for use when oral administration is not feasible or when a rapid high serum concentration of erythromycin is required for treating infections caused by specific sensitive microbial strains [1] - It is also indicated for the prevention of initial rheumatic fever, recurrence of rheumatic fever, and bacterial endocarditis [1] Group 2: Financial and Market Data - As of December 2025, the cumulative R&D investment for this drug by the group is approximately RMB 6.33 million (unaudited) [1] - According to IQVIA CHPA data, the sales revenue for injectable erythromycin lactobionate in mainland China (excluding Hong Kong, Macau, and Taiwan) is projected to be around RMB 170 million in 2024 [1]

Core Viewpoint - A new private equity fund named Zhonghui Fuhong (Tianjin) Equity Investment Fund Partnership (Limited Partnership) has been established, focusing on equity investment, investment management, and asset management activities [1] Group 1: Fund Details - The fund has a total investment amount of 547 million yuan [1] - The executing partner is Hongyi Private Equity Fund Management (Tianjin) Partnership (Limited Partnership) [1] - The fund's partners include Zhonghui Life Insurance Co., Ltd., Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., and Hongyi Private Equity Fund Management (Tianjin) Partnership (Limited Partnership) [1]

Group 1 - The core announcement is that Fosun Pharma's subsidiary, Suzhou Erye Pharmaceutical Co., Ltd., has had its drug registration application for injectable lactulose erythromycin accepted by the National Medical Products Administration [1] - The drug is intended for use when oral administration is not feasible or when a rapid high serum concentration of erythromycin is required for treating infections caused by specific sensitive microbial strains, as well as for preventing rheumatic fever and bacterial endocarditis [1] - As of December 2025, the cumulative R&D investment for this drug by the group is approximately RMB 6.33 million (unaudited) [1] Group 2 - According to the latest data from IQVIA CHPA, the sales revenue for injectable lactulose erythromycin in mainland China (excluding Hong Kong, Macau, and Taiwan) is projected to be approximately RMB 170 million in 2024 [1]

Core Viewpoint - Fosun Pharma's subsidiary, Suzhou Er Ye Pharmaceutical, has recently had its drug registration application for injectable lactulose erythromycin accepted by the National Medical Products Administration of China [1] Group 1: Drug Information - The drug is a chemical medication intended for use when oral administration is not feasible or when a rapid high serum concentration of erythromycin is required to treat infections caused by specific sensitive microbial strains [1] - It is also indicated for the prevention of initial rheumatic fever, recurrence of rheumatic fever, and bacterial endocarditis [1] Group 2: Financials and Market Potential - As of December 2025, the cumulative R&D investment for this drug by the group is approximately RMB 6.33 million (unaudited) [1] - According to the latest data from IQVIA CHPA, the sales revenue of injectable lactulose erythromycin in mainland China (excluding Hong Kong, Macau, and Taiwan) is projected to be around RMB 170 million in 2024 [1]

Group 1 - The core point of the article is that Fosun Pharma's subsidiary, Suzhou Er Ye Pharmaceutical Co., has recently had its drug registration application for injectable lactulose erythromycin accepted by the National Medical Products Administration of China [1] - The drug is intended for use in treating infections caused by specific microbial strains when oral administration is not feasible or when a rapid increase in serum erythromycin concentration is required [1] - The drug also aims to prevent the initial onset and recurrence of rheumatic fever, as well as to prevent bacterial endocarditis [1] Group 2 - As of December 2025, the cumulative R&D investment for this drug by the group is approximately RMB 6.33 million (unaudited) [1] - According to IQVIA CHPA data, the projected sales for injectable lactulose erythromycin in mainland China (excluding Hong Kong, Macau, and Taiwan) is approximately RMB 170 million in 2024 [1]